Free Trial
LON:VRP

Verona Pharma plc (VRP.L) (VRP) Share Price, News & Analysis

Verona Pharma plc (VRP.L) logo

About Verona Pharma plc (VRP.L) (LON:VRP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
55
55
52-Week Range
N/A
Volume
70,791 shs
Average Volume
150,610 shs
Market Capitalization
£228 million
Assets Under Management
N/A
Dividend Yield
N/A
Net Expense Ratio
0.00%
Aggregate Rating
N/A

ETF Overview

Receive VRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma plc (VRP.L) and its competitors with MarketBeat's FREE daily newsletter.

VRP ETF News Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Verona Pharma price target raised to $72 from $44 at Canaccord
See More Headlines

VRP ETF - Frequently Asked Questions

Verona Pharma plc (VRP.L) (LON:VRP) posted its quarterly earnings results on Thursday, February, 27th. The company reported ($30.30) EPS for the quarter, beating the consensus estimate of ($30.80) by $0.50.

Shares of VRP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma plc (VRP.L) investors own include Verona Pharma PLC American Depositary Share (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (LON:VRP) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners